Biotechnology Portfolio, Series 64
Ticker Symbol: FWECAX
25 Holdings (As of Day of Deposit) |
Ticker |
Company Name |
Initial
Weight |
Price* |
ABBV |
AbbVie Inc. |
4% |
$159.62 |
ACAD |
ACADIA Pharmaceuticals Inc. |
4% |
16.71 |
ADMA |
ADMA Biologics, Inc. |
4% |
6.55 |
ALKS |
Alkermes Plc |
4% |
24.68 |
ALNY |
Alnylam Pharmaceuticals, Inc. |
4% |
143.31 |
AMGN |
Amgen Inc. |
4% |
269.98 |
ARGX |
argenx SE |
4% |
372.80 |
TECH |
Bio-Techne Corporation |
4% |
64.06 |
BIIB |
Biogen Inc. |
4% |
208.90 |
BMRN |
BioMarin Pharmaceutical Inc. |
4% |
80.91 |
CSLLY |
CSL Limited |
4% |
89.60 |
EXEL |
Exelixis, Inc. |
4% |
23.70 |
GMAB |
Genmab A/S |
4% |
28.15 |
GILD |
Gilead Sciences, Inc. |
4% |
65.42 |
HALO |
Halozyme Therapeutics, Inc. |
4% |
38.57 |
INCY |
Incyte Corporation |
4% |
51.68 |
IQV |
IQVIA Holdings Inc. |
4% |
234.88 |
MRNA |
Moderna, Inc. |
4% |
107.97 |
NTRA |
Natera, Inc. |
4% |
91.66 |
NBIX |
Neurocrine Biosciences, Inc. |
4% |
135.99 |
REGN |
Regeneron Pharmaceuticals, Inc. |
4% |
883.20 |
SRPT |
Sarepta Therapeutics, Inc. |
4% |
128.77 |
TMO |
Thermo Fisher Scientific Inc. |
4% |
573.60 |
UTHR |
United Therapeutics Corporation |
4% |
233.85 |
VRTX |
Vertex Pharmaceuticals Incorporated |
4% |
397.48 |
* As of the close of business on 4/26/24.
Market values are for reference only and are not indicative of your individual
cost basis.
Not FDIC Insured Not Bank Guaranteed May Lose Value |
Portfolio Summary |
Initial Date of Deposit |
4/29/2024 |
Initial Public Offering Price |
$10.00 per Unit |
Portfolio Ending Date |
4/29/2026 |
Cash CUSIP |
30335K280 |
Reinvestment
CUSIP |
30335K298 |
Fee Account Cash CUSIP |
30335K306 |
Fee Account Reinvestment
CUSIP |
30335K314 |
Sales Charges (based on a $10 public offering
price) |
Standard Accounts |
Transactional sales charges |
Initial: |
0.00% |
|
Deferred: |
2.25% |
Creation and Development Fee (C&D Fee) |
|
0.50% |
Maximum Sales Charge |
|
2.75% |
Fee/Wrap Accounts |
Maximum Sales Charge |
|
0.50% |
The deferred sales charge will be deducted in three monthly installments commencing 8/20/24. When the
public offering price is less than or equal to $10.00 per unit, there will be no initial sales charge. If the price
exceeds $10.00 per unit, you will pay an initial sales charge. The maximum sales charge for investors in fee
accounts consists of the C&D fee. Investors in fee accounts are not assessed any transactional sales charges.
Standard accounts sales charges apply to units purchased as an ineligible asset. The C&D fee is a charge of
$0.050 per unit collected at the end of the initial offering period. If the price you pay exceeds $10.00 per
unit, the C&D fee will be less than 0.50%; if the price you pay is less than $10.00 per unit, the C&D fee will
exceed 0.50%. In addition to the sales charges listed, UITs are subject to annual operating expenses and
organization costs.
You should carefully consider the portfolio's investment objectives,
risks, and charges and expenses before investing. Contact your financial professional
or call First Trust Portfolios L.P. at 1.800.621.1675 to request a prospectus,
which contains this and other information about the portfolio. Read it carefully
before you invest.
Risk Considerations
An investment in this unmanaged unit investment trust should be made
with an understanding of the risks involved with owning common stocks, such as an economic recession and
the possible deterioration of either the financial condition of the issuers of the equity securities or the general
condition of the stock market.
You should be aware that the portfolio is concentrated in biotechnology and pharmaceutical companies in the health care sector which involves additional risks, including limited diversification. The companies engaged in the
biotechnology and pharmaceutical industries are subject to fierce competition, substantial research and development costs, governmental regulations, pricing constraints, and their products and services may be subject to
rapid obsolescence. Biotechnology and pharmaceutical stocks have experienced extreme price and volume fluctuations that are often unrelated to their operating performance. In addition, health crises, such as a pandemic
outbreak, can severely impact the health care industry in particular.
Securities of non-U.S. issuers are subject to additional risks, including currency fluctuations, political risks, withholding, the lack of adequate financial information, and exchange control restrictions impacting non-U.S. issuers.
An investment in a portfolio containing small-cap and mid-cap companies is subject to additional risks, as the share prices of small-cap companies and certain mid-cap companies are often more volatile than those of larger
companies due to several factors, including limited trading volumes, products, financial resources, management inexperience and less publicly available information.
Large capitalization companies may grow at a slower rate than the overall market.
As the use of Internet technology has
become more prevalent in the course of
business, the trust has become more
susceptible to potential operational risks
through breaches in cybersecurity.
Ongoing armed conflicts between Russia and Ukraine in Europe and among Israel, Hamas and other militant groups in the Middle East, have caused and could continue to cause significant market disruptions and volatility
within the markets in Russia, Europe, the Middle East and the United States. The hostilities and sanctions resulting from those hostilities could have a significant impact on certain investments as well as performance.
The ongoing effects of the COVID-19 global pandemic, or the potential impacts of any future public health crisis, may cause significant volatility and uncertainty in global financial markets. While vaccines have been developed, there is no guarantee that vaccines will be effective against future variants of the disease.
The value of the securities held by the
trust may be subject to steep declines or
increased volatility due to changes in
performance or perception of the issuers.
This UIT is a buy and hold strategy and investors should consider their ability to hold the trust until maturity.
There may be tax consequences unless units are purchased in an IRA or other qualified plan.